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1. Introduction 
Transplantation of stem cells may provide cures for the damaged Central nervous system 
(CNS). They hold an enormous potential in cell replacement therapy following traumatic 
brain injury (TBI) and received a great scientific and public interest in recent years. TBI 
remains the leading cause of long-term neurological disabilities, including cognitive, 
sensory, motor and emotional impairments among children and young adults. It has been 
suggested that stem cells hold great potential for the repair of the damaged nervous system. 
The therapeutic potential of stem cells has been examined in experimental brain injury using 
a variety of approaches. Although these results emphasized their potential therapeutic role 
in traumatic brain injury, crucial mechanism on how stem cells take effect, e.g. timing of 
stem cell implanation, stem cell survival and integration, effect of brain microenvironment 
and local trophic support, will be explained in this Overview of Different In-vivo/In-vitro 
Experimental Settings. 
TBI is the leading cause of death and disability worldwide (Bruns 2003). Thus, TBI is a 
highly relevant medical and socio-economic problem of modern society. During the last two 
decades, improvements in acute pre- and inhospital care, time management, diagnostic 
procedures, and rehabilitation strategies have substantially improved the level of care and 
outcome following TBI (Maegele 2007). But still, to date, no therapeutic approach has been 
proven effective in reversing the pathologic cellular sequelae underlying the progression of 
cell loss and in improving neurobehavioral outcome. As the brain has limited capacity for 
self-repair, restorative approaches with focus on replacement and repair of dysfunctional 
and dead cells by transplantation of cells (eg stem cells) into the traumatically injured brain 
have been studied. In the last 15 years various types of cells have been tested for their 
potential to restore the function in animal models after TBI. These cells include fetal cells, 
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In the traumatically injured brain, several experimental studies have been performed using 
engrafted hNT cells. These are post-mitotic human neurons (NT2N cells, commercially 
known as hNT cells, or LBS-neurons; Layton Bioscience Inc., Palo Alto, CA), derived from a 
human embryonal teratocarcinoma line (NT2 cell line) and differentiated into an exclusively 
neuronal phenotype by retinoic acid treatment in vitro (Trojanowski 1993). These cells 
appear to possess many of the key features of normal developing and mature human 
neurons, and survive up to 1 year in the brain after transplantation in immunodeficient 
neonatal or adult mice (Trojanowski et al., 1997). Muir (1999) first transplanted hNT cells 
into the injured cortex at 24 h after lateral Fluid Percussion (FP) brain injury in adult rats. 
The hNT transplant remained viable for up to 2 weeks, although no significant effect on 
acute posttraumatic neurologic motor function was observed. A follow-up study reported 
long-term (4-week) survival of hNT cells transplanted into the injured cortex 24 h following 
lateral FP brain injury in non-immunosuppressed adult rats. Integration of the graft in the 
peri-injured cortex was noted, again without significant improvement in motor or cognitive 
function (Philips 1999). More recently, hNT cells genetically engineered ex vivo to express 
NGF, transplanted into the medial septum at 24 h following Controlled Cortical Impact 
(CCI) brain injury in mice, attenuated cognitive dysfunction for up to 4 weeks post-
transplant (Watson 2003; Longhi 2005).  
Bone marrow stromal cells (BMSCs) have been evaluated in the CCI model of TBI in adult 
rats, administered by intra-arterial or intravenous injection at 24 h post-injury were 
subsequently found in multiple organs, including the brain. In these studies, 
improvement of neurological outcome and cellular expression of both the neuronal 
marker NeuN and the astrocytic marker GFAP in the engrafted cells were observed at 1 
and 2 weeks post-administration (Lu 2001; Mahmood 2001). Intraparenchymal 
transplantation of whole bone marrow into the pericontusional tissue at 24 h after CCI 
brain injury in rats also resulted in improved functional outcome and differentiation of 
transplanted cells into populations of cells expressing neuronal and glial markers up to 4 
weeks post-transplantation (Mahmood 2001).The mechanism by which BMSCs limit 
damage or promote repair has been suggested to be either via cell replacement by 
proliferation and differentiation of transplanted BMSCs into the phenotype of the 
damaged and/or lost cells, via trophic support, or via manipulation of the environment to 
stimulate endogenous regeneration (Hofstetter 2002). However, Breitbach showed, that 
the developmental fate of BM-derived cells is not restricted by the surrounding tissue and 
that the MSC fraction may underlie extended bone formation. These findings seriously 
question the biologic basis and clinical safety of using BM and in particular MSCs to treat 
nonhematopoietic disorders (Breitbach 2007). 
Immortalized cells, eg HiB5 cells, derived from the embryonic rat hippocampus and 
conditionally immortalized, were first transplanted into the neonatal brain, where they 
acquired neuronal and glial morphologies appropriate to the site of transplantation. Stable 
transduction of HiB5 cells to secrete (Nerve Growth Factor) NGF in vivo have been 
observed up to 9 months following transplantation into the medial septum, resulting in a 
prevention or reversal of cholinergic neuronal atrophy and related behavioral impairments 
normally occurring with age (Martinez-Serrano 1996, 1998). In non-immunosuppressed rats 
subjected to lateral FP brain injury, HiB5-NGF cells were transplanted in the injured cortex, 
24 h after injury (Philips 2001). Thereby brain-injured animals receiving either the HiB5-
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NGF cells or untransduced HiB5 cells showed significant improvements in neuromotor 
function and spatial learning, but hippocampal cell death was significantly reduced only in 
the HiB5-NGF cell transplant group, indicating that the transplantation of HiB5 cells 
genetically engineered to secrete trophic factors may have behavioral and neuroprotective 
effects after brain injury (Philips 2001). 
The C17.2 cell is a clonal multipotent progenitor cell derived from the external germinal 
layer of the neonatal murine cerebellum, immortalized by retroviral transduction of the 
avian gene myc (Ryder 1990). The cells were also marked with a second retrovirus for 
expression of bacterial X-galactosidase. A recent study form our working group has 
evaluated the behavioral effects of engrafted C17.2 cells following experimental TBI. In 
adult mice subjected to CCI brain injury, transplantation of C17.2 cells into the cortex 
(either ipsilateral or contralateral to the injury) at 3 days after injury significantly 
improved motor function but not cognitive function over a 12-week post-transplantation 
period (Riess 2002). Following engraftment, the C17.2 cells expressed either neuronal or 
astrocytic markers when transplanted ipsilateral to the lesion, while after contralateral 
transplantation only neuronal differentiation was observed.  
Pluripotent murine embryonic stem cells (ESC) have been shown to survive in the 
implanted healthy and hypoxic injured brain. Furthermore they differentiate into neural cell 
types following transplantation into rat brains in an experimental stroke model. 
Additionally it was shown, that they migrate along the corpus callosum to the ventricular 
walls and they populate the border zone of the damaged brain tissue on the hemisphere 
opposite to the implantation site, indicating that ES cells have high migrational dynamics 
(Hoehn 2002, Erdoe 2003). Based on these results, our working group has implanted these 
undifferentiated, eGFP-expressing ES-D3 cells into the ipsi- or contra-lateral cortex of rat 
brains following the induction of a moderate lateral fluid-percussion (FP) brain injury (Riess 
2007, Molcanyi 2007).  
As one result we were able to show, that the differentiation and integration of 
transplanted ES-D3 cells was barely observed at any time point. But sporadic tumor 
formation was observed. However, ES-D3 cell grafted animals demonstrated a significant 
improvement in functional outcome on a range of behavioral tasks. Motor function 
improvements were observed as early as one week following implantation. Other 
observers are reporting that transplantation of pre-differentiated ES cells improved 
behavioural outcome on sensorimotor and locomotor tests but failed to improve cognitive 
function during memory tasks assessed by Morris water maze (Hoane 2004). An 
improvement of motor function was also demonstrated when motoneuron enriched 
neural cells derived from mouse embryonic stem cells were transplanted after cryogenic 
brain injury (Chiba 2003). 
However, the success of TX depends not only on cell type and their differentiation state, but 
also on several other important parameters, such as inflammatory response after injury, 
microenvironment of the host tissue, time window for TX, immune response to cell TX, 
immunosuppression, site of TX.  
2. Location for TX 
Miyazono (Miyazono 1995) demonstrated that the proliferation, differentiation and 
survival of implanted cells were modulated by the anatomical target site into which the 
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grafts were placed. The implantation of undifferentiated Ntera-derived cells into rat 
cortex resulted into formation of lethal tumors within 70 days posttransplantation. In 
contrast, the same cells implanted into caudoputamen ceased to proliferate and 
progressively differentiated into postmitotic neuron-like cells. Following transplantation 
of C17.2 NSCs following CCI brain injury, our working group was able to show, that cell 
differentiation depends on the location of the implantation site. Thirteen weeks after the 
transplantation under the contusion cavity, NSCs were found in the ipsilateral 
hippocampus and in the cortical parenchyma adjacent to the injury cavity. NSCs 
transplanted into the contralateral hemisphere were also detected in the contralateral 
hippocampus and the contralateral cortex. The NSCs in the injured cortex were found to 
express neuronal and astrocytic markers, implicating differentiation into neurons and 
glia, whereas the NSCs transplanted into the uninjured contralateral cortex showed an 
almost exclusively neuronal phenotype. The reasons underlying these apparent variations 
in differentiation remain unclear, although the demand for both neurons and glial cell 
replacement may be far greater in the areas of the injured hemisphere that have sustained 
significant tissue loss. 
3. Timepoint for TX 
Beyond cell specific effects on functional improvement following TX Soares and 
coworkers suggested that an optimal time window for TX may exist (Soares 1991). 
However, studies evaluating optimal time for transplantation in models of experimental 
TBI are still pending. In most studies cells were implanted between 24 and 72 hours 
following TBI. However this relatively early time point for transplantation may be 
appropriate for avoiding the peak of any inflammatory reaction and may allow the 
integration, migration and differentiation of cells prior to formation of the astroglial scar 
that may counteract these processes. Glial scar formed by CNS injury is considerd as the 
main inhibitory barrier of nerve regeneration. Many efforts have been made to prevent 
scarring and to pomote axonal regeneration after injury (see review: Sofroniew 2010). In 
their experiment, Soares and coworkers demonstrated that there is a temporal window in 
which fetal cortical transplants can attenuate glial scarring as well as be successfully 
incorporated into host brains following FP injury. They showed that cells transplanted 
two days, one week and two weeks after injury survived and were incorporated into the 
host tissue whereby the cells transplanted at later time points (4 weeks) failed to 
incorporate. This phenomenon was explained by the fact that there was a little evidence of 
a glial scar formation at day two and one week time points, whereas the scarring raised 
significantly thereafter (Soares 1991). More evidence for a optimal time window for TX is 
shown by comparing the following experiments in experimental Spinal Cord Injury. Han 
(Han 2002) reported that immediately TX of neuronal restricted progenitors (NRPs) after 
injury gives rise to neurons and survived for at least one month. However, after 
transplantation 10 days after spinal cord injury, NRPs did not give rise to neurons, 
suggesting that the environment of the injured spinal cord influences the implanted cells 
(Cao 2002). The influence of ES cells due to host environment was also proven in the 
following in vitro experiment. Hereby, we have shown that the extract derived from rat 
brains in the acute phase following TBI impairs survival of undifferentiated murine ES 
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cells and induces rapid differentiation of surviving cells. This observation suggests that 
during the early acute phase of traumatic injury the cerebral environment contains 
detrimental as well as protective signals that may induce neurogenic processes following 
ES cell transplantation (Bentz 2010). However, it is also likely that different cell types will 
have different transplantation time points for optimal survival, migration, and 
proliferation. For example, bone marrow-derived stem cells (BMSCs) have been suggested 
to engraft better as damage progresses in injured tissue (Prockop 2002).  
4. Inflammatory response 
Inflammatory leukocytic recruitment and diffuse neuronal degeneration are pathological 
processes resulting from TBI. While the normal brain is generally considered to be a 
relatively immunologically privileged organ, the injured brain is certainly not. The presence 
of an inflammatory response in the injured parenchyma may increase damage of the host 
brain in the early post-traumatic phase, while becoming more beneficial in the chronic phase 
(Allan 2001, Lenzlinger 2001). The effects of this inflammatory reaction on the graft survival 
following TX are still poorly understood. Our working group examined the time dependent 
fate of ES cells following ipsi- and contralateral implantation into rat brains injured via FP 
injury. Double-staining for GFP and macrophage antigens revealed stem cells phagocytosed 
by infiltrated and activated macrophages, indicating the loss of implanted stem cells was 
due to an early posttraumatic inflammatory response. Macrophage infiltration was shown to 
be less pronounced when stem cells were implanted into completely intact healthy brains. 
We therefore suggested that the massive macrophage infiltration at graft sites might be 
ascribed to the combined stimulus exhibited by the FP brain injury and the cell implantation 
(Molcanyi 2009). 
5. Tumor formation 
It has to be taken into consideration that the highly proliferative characteristics (selfrenewal 
potential) of ES cells combined with the ability to differentiate into all embryonic germinal 
layers (pluripotency) present a potential threat of tumor development (teratoma, 
teratocarcinoma) when they are transplanted into the adult CNS. However, tumorigenesis 
has been observed after implantation of undifferentiated human ESCs into healthy rat 
brains, giving rise to teratomas and malignant teratocarcinomas (Thomson 1998). 
Accordingly, Erdö compared the tumorigenic outcome after implantation of D3, clone BAC-
7 ESCs in a homologous (mouse to mouse) vs. xenogeneic (mouse to rat) stroke model. In 
injured and healthy mouse brains, both transplanted undifferentiated and pre-differentiated 
murine ESCs produced highly malignant teratomas, while mouse ESCs xenotransplanted 
into injured rat brain migrated towards the lesion and differentiated into neurons at the 
border zone of the ischemic infarct, suggesting that tumorigenesis may be related to the host 
animal rather than to the differentiation status of the implanted cells (Erdo 2003)  
Our scientific group has repeated an analogous experiment in the model of traumatic brain 
injury vs. healthy rat brain. After TBI we observed a scarce tumor formation, but in healthy 
rat brains the above mentioned cell line lead to formation of malignant teratocarcinomas in 
the majority of engrafted animals. The absence of tumor formation in animals suffering from 
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traumatic brain injury was linked to the already described inflammatory response. As we 
believe, the tumorigenic fraction of implanted graft may have been scavenged by activaed 
macrophages, alongside with concomitant survival of stem cells turning into healthy neural 
phenotypes. Great caution is needed when stem cells are implanted in experimental settings 
of diseases associated with inflammatory response (such as stroke or traumatic brain injury) 
as the tumorigenic threat may stay unveiled (in case tumorigenic fraction is being removed 
by activated immune cells) (Molcanyi 2009). 
6. Functional outcome 
Neurobehavioral assessment of outcome has always played an integral part in traumatic 
brain injury (TBI) research (Hamm 2001).  
After transplantation of the C17.2 Neural Stem Cells intracerebrally in the acute period after 
TBI we were able to show, that these cells survive, differentiate, and attenuate posttraumatic 
neurological deficits in the chronic postinjury period. Brain-injured mice that received NSC 
transplants showed significantly improved performance in the rotating pole test during the 
8-week observation period. In addition, brain-injured animals that received NSCs in the 
ipsilateral hemisphere exhibited improved performance in the rotarod test during the 12-
week observation period. Similar effects were achieved by, transplantation of 
undifferentiated ES cells following experimental traumatic brain injury. Hereby the TX 
significantly attenuates the impairment of motor function. Performance on the rotarod test 
and sensorimotor scores improved significantly when brain injured animals received ES 
cells. This is in accordance with previous brain injury studies that also reported recovery of 
function following cell transplantation. Improved behavioural outcome on sensorimotor 
and locomotor tests in brain injured animals was also demonstrated following 
transplantation of pre-differentiated ES cells, or minced fetal cortical grafts (E16), 
respectively (Hoane  2004).  
But, the effects on neurobehavior outcome can be influenced by the medication the animals 
receive. Cyclosporin A (CsA) is widely used in clinical situations to attenuate graft rejection 
following organ and central nervous system transplantation. Therefore, we evaluated the 
influence of post-injury CsA administration on behavioral recovery after TBI. Hereby we 
found that, injured animals treated with CsA showed a significant improvement in motor 
function and in sensorimotor function, when compared to vehicle treated, injured animals. 
In conclusion, the treatment with CsA improves certain aspects of motor and sensorimotor 
function following experimental TBI. Therefore in animal studies analyzing functional 
outcome, these effects have to be controlled for (Riess 2001). 
However, all the mechanisms of how stem cells attenuate a neurologic impairment are not 
completely clarified, yet. In the light of the recent data, the true cell replacement of 
lost/injured tissue seems to be highly unlikely. Humoral/trophic mechanisms accompanied 
by cell-cell interactions have been proposed to play a central role of stem cell grafting effect. 
Our scientific group has investigated the behaviour of stem cells in-vitro after conditioning 
with the cerebral extract derived from healthy and injured rat brain. Stimulated cells have 
produced statistically significant amounts of various neurotrophic factors, proving this 
phenomena to be possibly one of the regenarative mechanisms following stem cell 
transplantation (Bentz 2007). 
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7. Conclusion and further prospectives 
In the present review we have summarized our experience with in-vivo and in-vitro set-
ups of cell therapy in TBI. Our results demonstrate the influence of brain 
microenvironment on alterations on stem cell fate, the significance of appropriate 
timepoint for TX and the effect of the time dependent inflammatory response following 
TBI. However, despite the promising results concerning functional improvement 
following ES cell TX following TBI the clinical use of ES cells is complicated due to ethical 
and immunological concerns (Molcanyi 2007, Riess 2007, Erdö 2003). These concerns 
might be overcome by using autologous pluripotent stem cells derived from a patient's 
own somatic cells by ectopic expression of pluripotency factors (Hochedlinger 2006). 
These, induced pluripotent stem (iPS) cells are widely recognised as a powerful 
alternative to ES cells as potential therapeutic agents, with unique advantages. Like ES 
cells, they are pluripotent and can be used to obtain tissue-specific cells or progenitors of 
therapeutic interest (such as neurons and their progenitors). But on the other side, iPS 
cells are likely to carry a higher risk of tumorigenicity than ES cells, due to the 
inappropriate reprogramming of these somatic cells, the activation of exogenous 
transcription factors, or other reasons (Tsuji 2010). In a most recent study it has been 
shown that the transplantation of iPS-derived neurospheres into the spinal cord directly 
after contusive injury in mice resulted in cell differentiation into all three neural lineages 
without forming teratomas or other tumors. These cells also participated in remyelination 
and induced the axonal regrowth of host 5HT-positive serotonergic fibers, promoting 
locomotor function recovery. These findings suggest that iPS cell-derived neurospheres 
may be a promising cell source for therapy of spinal cord injury (Tsuji 2010). It is required, 
that the therapeutic potency of these cell-source will also be evaluated in models of TBI to 
prove their effectiveness and safety as a clinical therapy for human after TBI.  
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